Cellarity

Cellarity is pioneering a fundamentally new approach to drug discovery by focusing on the cell as the central unit of biology. Founded in 2017 as a Flagship Pioneering company, Cellarity combines high-resolution data, single-cell technologies, and machine learning to unveil the network state of a cell, enabling a more comprehensive understanding of disease and drug action. The company's proprietary platform, Cellarity™, maps and models cell behaviors across a wide range of diseases, allowing for the discovery of completely new types of medicines. This approach represents a shift from traditional drug discovery methods that target single molecular mechanisms. Cellarity's technology can predict cellular behavior changes in response to various perturbations, including genetic alterations and drug treatments. The company is developing a pipeline of drug candidates across various therapeutic areas, including metabolic disease, hematology, immuno-oncology, and respiratory diseases. By focusing on cell behavior rather than individual protein targets, Cellarity aims to address previously intractable diseases and develop more effective treatments with fewer side effects. The company's innovative approach has attracted significant investment and partnerships, positioning Cellarity as a leader in the next generation of drug discovery and development.